FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE DECANOATE changes extrapyramidal adverse effects ‐ general compared with ORAL NEUROLEPTICS (very low certainty).
1 finding from 1 review
- Fluphenazine decanoate (depot) and enanthate for schizophrenia 2015 · Cochrane Headline outcomes onlyRR 0.47 [0.24, 0.91]3 studies · 259 participantsVery low